Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar;72(3):268-75.
doi: 10.1001/jamapsychiatry.2014.2427.

Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes

Affiliations

Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes

Elaine Setiawan et al. JAMA Psychiatry. 2015 Mar.

Abstract

Importance: The neuroinflammatory hypothesis of major depressive disorder is supported by several main findings. First, in humans and animals, activation of the immune system causes sickness behaviors that present during a major depressive episode (MDE), such as low mood, anhedonia, anorexia, and weight loss. Second, peripheral markers of inflammation are frequently reported in major depressive disorder. Third, neuroinflammatory illnesses are associated with high rates of MDEs. However, a fundamental limitation of the neuroinflammatory hypothesis is a paucity of evidence of brain inflammation during MDE. Translocator protein density measured by distribution volume (TSPO VT) is increased in activated microglia, an important aspect of neuroinflammation.

Objective: To determine whether TSPO VT is elevated in the prefrontal cortex, anterior cingulate cortex (ACC), and insula in patients with MDE secondary to major depressive disorder.

Design, setting, and participants: Case-control study in a tertiary care psychiatric hospital from May 1, 2010, through February 1, 2014. Twenty patients with MDE secondary to major depressive disorder and 20 healthy control participants underwent positron emission tomography with fluorine F 18-labeled N-(2-(2-fluoroethoxy)benzyl)-N-(4-phenoxypyridin-3-yl)acetamide ([18F]FEPPA). Patients with MDE were medication free for at least 6 weeks. All participants were otherwise healthy and nonsmokers.

Main outcomes and measures: Values of TSPO VT in the prefrontal cortex, ACC, and insula.

Results: In MDE, TSPO VT was significantly elevated in all brain regions examined (multivariate analysis of variance, F15,23 = 4.5 [P = .001]). The magnitude of TSPO VT elevation was 26% in the prefrontal cortex (mean [SD] TSPO VT, 12.5 [3.6] in patients with MDE and 10.0 [2.4] in controls), 32% in the ACC (mean [SD] TSPO VT, 12.3 [3.5] in patients with MDE and 9.3 [2.2] in controls), and 33% in the insula (mean [SD] TSPO VT, 12.9 [3.7] in patients with MDE and 9.7 [2.3] in controls). In MDE, greater TSPO VT in the ACC correlated with greater depression severity (r = 0.63 [P = .005]).

Conclusions and relevance: This finding provides the most compelling evidence to date of brain inflammation, and more specifically microglial activation, in MDE. This finding is important for improving treatment because it implies that therapeutics that reduce microglial activation should be promising for MDE. The correlation between higher ACC TSPO VT and the severity of MDE is consistent with the concept that neuroinflammation in specific regions may contribute to sickness behaviors that overlap with the symptoms of MDE.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement: JHM, AAW and SH have received operating grant funds for other studies from Eli-Lilly, GlaxoSmithKline, Bristol Myers Squibb, Lundbeck, and SK Life Sciences in the past 5 years. JHM has consulted to several of these companies as well as Takeda, Sepracor, Trius, Mylan and Teva. None of these companies participated in the design or execution of this study or in writing the manuscript. All authors declare no conflicts of interest.

Figures

Figure 1
Figure 1. Elevated translocator protein density (TSPO VT) during a major depressive episode (MDE) secondary to major depressive disorder (MDD)
TSPO VT was significantly greater in MDE of MDD (Depressed, N=20, 15 HAB, 5 MAB) compared to controls (Healthy, N=20, 14 HAB, 6 MAB): ANOVAs, aprefrontal cortex, F1,37 = 8.07, P = 0.007; banterior cingulate cortex, F1,37 = 12.24, P = 0.001; cinsula, F1,37 = 12.34, P = 0.001; ddorsal putamen, F1,37 =14.1, P=0.001; eventral striatum, F1,37 =6.9, P=0.013; fthalamus, F1,37 =13.6, P=0.001; ghippocampus, F1,37 =7.5, P=0.009. All second generation TSPO radioligands, such as [18F]FEPPA, show differential binding according to the SNP rs6971 of the TSPO gene resulting in high affinity binders (HAB) and mixed affinity binders (MAB). Red bars indicate means in each group.
Figure 2
Figure 2. Relationship between regional translocator protein density (TSPO VT) and symptoms of current major depressive episode
TSPO VT in the anterior cingulate cortex was positively related to scores on the 17-item Hamilton Depression Rating Scale (HDRS), after correcting for rs6971 genotype (r=0.628, P=0.005). All second generation TSPO radioligands, such as [18F]FEPPA, show differential binding according to the SNP rs6971 of the TSPO gene resulting in high affinity binders (HAB) and mixed affinity binders (MAB).

References

    1. Ustun TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ. Global burden of depressive disorders in the year 2000. Br J Psychiatry. 2004;184:386–392. - PubMed
    1. Dwivedi Y. Brain-derived neurotrophic factor: role in depression and suicide. Neuropsychiatr Dis Treat. 2009;5:433–449. - PMC - PubMed
    1. MacQueen G, Frodl T. The hippocampus in major depression: evidence for the convergence of the bench and bedside in psychiatric research? Mol Psychiatry. 2011;16(3):252–264. - PubMed
    1. Meyer JH. Neuroimaging markers of cellular function in major depressive disorder: implications for therapeutics, personalized medicine, and prevention. Clin Pharmacol Ther. 2012;91(2):201–214. - PubMed
    1. Rajkowska G, Miguel-Hidalgo JJ. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets. 2007;6(3):219–233. - PMC - PubMed

Publication types